Allergic Rhinitis Drugs Market Forecast 2015-2025 : Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines

アレルギー性鼻炎治療薬の世界市場予測:抗ヒスタミン剤、コルチコステロイド、免疫療法、ワクチン

◆タイトル:Allergic Rhinitis Drugs Market Forecast 2015-2025 : Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines
◆商品コード:VGAIN5091105
◆調査・発行会社:visiongain
◆発行日:2015年9月
◆ページ数:326
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、アレルギー性鼻炎治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・アレルギー性鼻炎治療薬の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・アレルギー性鼻炎治療薬の世界市場:セグメント別市場分析
 (抗ヒスタミン剤、コルチコステロイド、免疫療法、ワクチン)
・地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Allergic Rhinitis drugs – new study showing you trends, partnerships, and predicted revenues
Where is the market for allergic rhinitis drugs heading? What are the commercial prospects for this market? Visiongain’s new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.

Our 326 page report provides 273 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess:
• Forecasted sales at world market, submarket, regional and national level
• You will see financial results and revenue predictions
• Interviews, trends, opportunities

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find:
• Original analyses, with business outlooks and developments
• Discover qualitative analyses (including SWOT and Porter’s Five Forces)
• Company profiles and commercial developments

Read the full transcript of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
• Tonya Winders, President and CEO, Allergy & Asthma Network
• Amena Warner, Nurse Advisor at Allergy UK and President, International Nurses Group in Immunodeficiencies
• Dr Apelle Econs MRCS LRCP, Consultant – Allergy & Nutrition, Allergy Medical UK

You will find prospects for key submarkets
In addition to analyses of the overall world market, you will see revenue forecasting of five world-level submarkets to 2025:
• Oral antihistamines
• Intranasal corticosteroids
• Immunotherapy & Vaccines
• Intranasal antihistamines
• Other allergic rhinitis drugs

Additionally, our new study provides global sales forecasts by volume for the intranasal corticosteroids and intranasal antihistamines submarkets, including individual global sales forecasts by volume for the leading drugs in these submarkets from 2015-2025.

Our investigation shows business research and analysis with individual revenue forecasts and discussions for each submarket.

See revenue forecasts for products
How will leading drugs perform to 2025 at world level? Our study forecasts sales of 25 marketed products, including these brands:
• Claritin/ Claritin OTC
• Allegra/ Allegra-D/ Allegra OTC
• Staloral
• Ragwitek
• Nasonex
• Omnaris
• Patanase
• Astepro
• Clarinex

Discover how high revenues can go. You will see what’s happening, understanding trends, challenges and opportunities.

What are the prospects for the leading regions and countries?
You will discover individual revenue forecasts for 12 leading national markets to 2025. There are many commercial opportunities to exploit in both developed and developing countries.
• US
• China
• Japan
• Germany
• India
• France
• UK
• Italy
• Spain
• Brazil
• Russia
• Mexico
• Rest of the World

Our analyses show that emerging economies, particularly in South America and Asia, will continue to achieve high revenue growth to 2025. Various economic, geographical, and regulatory factors globally will influence the market.

Leading companies and potential for market growth
We expect the rising prevalence and the consequent increase in demand for allergic rhinitis drugs, expanding healthcare coverage, the strength of the R&D pipeline and developments in drug delivery technologies to contribute to an increase in sales for allergic rhinitis drugs to 2025.

Our work shows you what organisations hold greatest potential. See profiles of 8 leading companies, including these:
• UCB
• Sanofi
• Kyowa Hakko Kirin
• GlaxoSmithKline
• ALK- Abelló
• Stallergenes
• Merck & Co
• Johnson & Johnson

A company profile gives you the following information:
• Revenue forecast for allergic rhinitis drugs from 2015 to 2025
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), and collaborations, including alliances, partnerships, and joint ventures
• Discussion of a company’s activities and outlook
• Allergic rhinitis drugs revenue forecast from 2015 to 2025

【レポートの目次】

1. Report Overview
1.1 Global
1.1 Global Allergic Rhinitis Drugs: Market Overview
1.2 Global Allergic Rhinitis Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction To Allergic Rhinitis Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Allergic Rhinitis Treatments – An Industry Overview
2.2 A Brief Overview Of Allergy
2.3 Allergic Rhinitis
2.3.1 The Global Prevalence Of Allergic Rhinitis
2.3.2 Pathophysiology Of Allergic Rhinitis: IgEs And Mast Cells
2.3.3 Symptoms Of Allergic Rhinitis
2.3.4 Classification Of Allergic Rhinitis
2.3.4.1 Non-Allergic Rhinitis And Mixed Rhinitis
2.3.5 Seasonal Allergic Rhinitis (Hay Fever)
2.3.6 Perennial Allergic Rhinitis
2.3.7 Diagnosis Of Allergic Rhinitis
2.4 Treatment Of Allergic Rhinitis
2.4.1 Antihistamines
2.4.1.1 First-Generation Antihistamines
2.4.1.2 Second- And Third-Generation Antihistamines
2.4.2 Corticosteroids
2.4.2.1 First-, Second- And Third-Generation Intranasal Corticosteroids
2.4.2.2 Combination Drug Products
2.4.3 Leukotriene Receptor Antagonists
2.4.4 Cromolyn (cromoglicic acid)
2.4.5 Decongestants
2.4.6 Saline Nasal Sprays
2.4.7 Immunotherapy And Vaccines
2.5 Phases Of Clinical Trials
2.6 Scope Of This Report

3. The Global Allergic Rhinitis Drugs Market, 2015-2025
3.1 The Global Allergic Rhinitis Drugs Market: Market Overview
3.2 Categorisation Of The Global Allergic Rhinitis Drugs Market
3.3 The Global Allergic Rhinitis Drugs Market In 2014
3.4 Leading Allergic Rhinitis Drugs, 2015
3.5 The Global Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
3.6 Allergic Rhinitis Drugs: Changing Market Shares By Sector 2015-2025

4. The Intranasal Antihistamines Market: Market Analysis And Forecast 2015-2025
4.1 Leading Products In The Intranasal Antihistamines Market, 2014
4.2 Intranasal Antihistamines: Market Trends And Developments, 2015
4.2.1 Azelastine Versus Olopatadine
4.2.2 Intranasal Combination Products
4.3 Intranasal Antihistamines: Market Forecast 2015-2025
4.3.1 Intranasal Antihistamines: Market Forecast by Volume, 2015-2025
4.3.2 Intranasal Antihistamines: Changing Market Shares By Leading Drugs 2015-2025
4.4 Leading Intranasal Antihistamines
4.5 Patanase (olopatadine) – Novartis
4.5.1 Patanase: Sales Forecast 2015-2025
4.6 Astepro (azelastine) – Meda Pharmaceuticals
4.6.1 Astepro: Sales Forecast 2015-2025
4.7 Astelin (azelastine) – Meda Pharmaceuticals
4.7.1 Astelin: Sales Forecast 2015-2025
4.8 Dymista (azelastine/fluticasone) – Meda Pharmaceuticals
4.8.1 Dymista: Sales Forecast 2015-2025
4.9 Generic Intranasal Azelastine
4.9.1 Generic Intranasal Azelastine: Sales Forecast By Value, 2015-2025
4.9.2 Generic Intranasal Azelastine: Sales Forecast By Volume, 2015-2025
4.10 Generic Intranasal Olopatadine
4.10.1 Generic Intranasal Olopatadine: Sales Forecast By Value, 2015-2025
4.10.2 Generic Intranasal Olopatadine: Sales Forecast By Volume, 2015-2025

5. Intranasal Corticosteroids Market: Market Analysis And Forecast 2015-2025
5.1 Leading Products In The Intranasal Corticosteroids Market, 2014
5.2 Intranasal Corticosteroids: Market Forecast 2015-2025
5.2.1 Intranasal Corticosteroids: Market Forecast by Volume, 2015-2025
5.2.2 Intranasal Corticosteroids: Changing Market Shares By Leading Drugs 2015-2025
5.3 Leading Intranasal Corticosteroids
5.4 Nasonex (mometasone) – Merck
5.4.1 Nasonex: Sales Forecast by Value, 2015-2025
5.4.2 Nasonex: Sales Forecast by Volume, 2015-2025
5.5 Avamys/Veramyst (fluticasone furoate) – GlaxoSmithKline
5.5.1 Avamys/Veramyst: Sales Forecast by Value, 2015-2025
5.5.2 Avamys/Veramyst: Sales Forecast by Volume, 2015-2025
5.6 Flixonase/Flonase/Flonase-OTC (fluticasone propionate) – GlaxoSmithKline
5.6.1 Flixonase/Flonase/Flonase-OTC: Sales Forecast By Value, 2015-2025
5.6.2 Flixonase/Flonase/Flonase-OTC: Sales Forecast By Volume, 2015-2025
5.7 Rhinocort (budesonide) – AstraZeneca
5.7.1 Rhinocort: Sales Forecast by Value, 2015-2025
5.7.2 Rhinocort: Sales Forecast by Volume, 2015-2025
5.8 Omnaris (ciclesonide) – Dainippon Sumitomo/Takeda
5.8.1 Omnaris: Sales Forecast By Value, 2015-2025
5.8.2 Omnaris: Sales Forecast By Volume, 2015-2025
5.9 Nasacort/Nasacort-OTC (triamcinolone) – Sanofi
5.9.1 Nasacort/Nasacort-OTC: Sales Forecast By Value, 2015-2025
5.9.2 Nasacort: Sales Forecast By Volume, 2015-2025
5.10 Beconase/Beconase AQ (beclometasone) – GlaxoSmithKline/Omega Pharma
5.10.1 Beconase/Beconase AQ: Sales Forecast By Value, 2015-2025
5.10.2 Beconase/Beconase AQ: Sales Forecast by Volume, 2015-2025
5.11 Qnasl (beclometasone) – Teva
5.11.1 Qnasl: Sales Forecast by Value, 2015-2025
5.11.2 Qnasl: Sales Forecast by Volume, 2015-2025
5.12 Zetonna (ciclesonide) – Dainippon Sumitomo
5.12.1 Zetonna: Sales Forecast By Value, 2015-2025
5.12.2 Zetonna: Sales Forecast By Volume, 2015-2025
5.13 Generic Intranasal Corticosteroids
5.13.1 Generic Intranasal Beclometasone
5.13.1.1 Generic Intranasal Beclometasone: Sales Forecast By Value, 2015-2025
5.13.1.2 Generic Intranasal Beclometasone: Sales Forecast By Volume, 2015-2025
5.13.2 Generic Intranasal Budesonide
5.13.2.1 Generic Intranasal Budesonide: Sales Forecast By Value, 2015-2025
5.13.2.2 Generic Intranasal Budesonide: Sales Forecast By Volume, 2015-2025
5.13.3 Generic Intranasal Flunisolide
5.13.3.1 Generic Intranasal Flunisolide: Sales Forecast By Value, 2015-2025
5.13.3.2 Generic Intranasal Flunisolide: Sales Forecast By Volume, 2015-2025
5.13.4 Generic Intranasal Fluticasone
5.13.4.1 Generic Intranasal Fluticasone: Sales Forecast By Value, 2015-2025
5.13.4.2 Generic Intranasal Fluticasone: Sales Forecast By Volume, 2015-2025
5.13.5 Generic Intranasal Mometasone
5.13.5.1 Generic Intranasal Mometasone: Sales Forecast By Value, 2015-2025
5.13.5.2 Generic Intranasal Mometasone: Sales Forecast By Volume, 2015-2025
5.13.6 Generic Intranasal Triamcinolone
5.13.6.1 Generic Intranasal Triamcinolone: Sales Forecast By Value, 2015-2025
5.13.6.2 Generic Intranasal Triamcinolone: Sales Forecast By Volume, 2015-2025

6. Oral Antihistamines Market: Market Analysis And Forecast 2015-2025
6.1 Oral Antihistamines: Market Overview
6.1.1 Leading Products In The Oral Antihistamines Market, 2014
6.2 Oral Antihistamines: Market Trends And Developments, 2015
6.2.1 Patent Expiries And The Threat Of Generics
6.2.2 The Increasing Switch From Prescription To Over-The-Counter Sales
6.2.3 The Potential For Combination Therapy With Intranasal Corticosteroids
6.3 Oral Antihistamines: Market Forecast 2015-2025
6.3.1 Oral Antihistamines: Changing Market Shares By Leading Drugs 2015-2025
6.4 Leading Oral Antihistamines For The Treatment Of Allergic Rhinitis
6.5 Allegra/Allegra-D/Allegra OTC (fexofenadine) – Sanofi
6.5.1 Allegra/Allegra OTC: Historical Sales, 1995-2014
6.5.2 Allegra/Allegra OTC: Sales Forecast 2015-2025
6.6 Zyrtec/Zyrtec D (cetirizine) – Johnson & Johnson/ UCB/ GSK
6.6.1 Zyrtec/Zyrtec D: Sales Forecast 2015-2025
6.7 Claritin/Claritin OTC (loratadine) – Bayer/ Merck & Co
6.7.1 Claritin/Claritin OTC: Sales Forecast 2015-2025
6.8 Xyzal (levocetirizine) – Sanofi/ UCB/ GSK
6.8.1 Xyzal: Sales Forecast 2015-2025
6.9 Allelock (olopatadine) – Kyowa Hakko Kirin
6.9.1 Allelock: Sales Forecast 2015-2025
6.10 Clarinex (desloratadine) – Merck & Co.
6.10.1 Clarinex: Sales Forecast 2015-2025
6.11 Ebastel (ebastine) – AstraZeneca/Takeda/Dainippon Sumitomo
6.11.1 Ebastel: Sales Forecast 2015-2025
6.12 Talion (bepotastine) – Mitsubishi Tanabe
6.12.1 Talion: Sales Forecast 2015-2025
6.13 Other Oral Antihistamines: Sales Forecast 2015-2025

7. Immunotherapy And Vaccines: Market Analysis And Forecast 2015-2025
7.1 Immunotherapy And Vaccines: Market Overview
7.1.1 Immunotherapy: Primed For Rapid Expansion
7.2 Leading Immunotherapy Products In The Allergic Rhinitis Market, 2014
7.3 Allergic Rhinitis Immunotherapy: Market Trends And Developments, 2015
7.3.1 Subcutaneous And Sublingual Immunotherapy
7.3.2 Expansion Into The US Market
7.3.3 Standardisation Of Immunotherapy Products
7.3.4 Immunotherapy As A Preventative Treatment
7.4 Allergic Rhinitis Immunotherapy: Market Forecast 2015-2025
7.4.1 Allergic Rhinitis Immunotherapy: Changing Market Shares By Leading Products 2015-2025
7.5 Immunotherapy Type – By Route Of Administration, 2014
7.6 Leading Immunotherapy Products For Allergic Rhinitis
7.7 Staloral (Grass pollen allergen extract) – Stallergenes
7.7.1 Staloral: Sales Forecast 2015-2025
7.8 Alutard SQ (Grass pollen allergen extract) – ALK-Abelló
7.8.1 Alutard SQ: Sales Forecast 2015-2025
7.9 Grazax/Grastek (Timothy grass pollen allergen extract) – ALK-Abelló/Merck
7.9.1 Grazax/Grastek: Sales Forecast 2015-2025
7.10 Oralair (Grass pollen allergen extract) – Stallergenes/Greer
7.10.1 Oralair: Sales Forecast 2015-2025
7.11 Ragwitek (Short ragweed pollen allergen extract) – Merck
7.11.1 Ragwitek: Sales Forecast 2015-2025
7.12 Other Allergic Rhinitis Immunotherapy Products: Sales Forecast 2015-2025

8. Leading National Markets For Allergic Rhinitis Drugs, 2015-2025
8.1 The Allergic Rhinitis Drugs Market By Region
8.1.1 The Global Distribution Of Allergic Rhinitis Drugs In 2014
8.2 Leading National Markets: Forecast 2015-2025
8.2.1 Changing Market Shares By Region, 2015-2025
8.3 Regional Allergic Rhinitis Drugs Markets: Analysis And Forecasts, 2015-2025
8.4 United States: The Largest Allergic Rhinitis Drugs Market
8.4.1 US Allergic Rhinitis Drugs Market: Trends And Developments
8.4.1.1 The Trend Of Rx-to-OTC Switching
8.4.2 US Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.5 EU5
8.5.1 EU5 Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025
8.5.2 Germany
8.5.2.1 Germany: Reform Of AMNOG Pharmaceutical Rebate Law
8.5.2.2 German Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.5.3 UK
8.5.3.1 UK: Increasing Burden Of Allergy
8.5.3.2 UK Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.5.4 France
8.5.4.1 France: Social Security Finance Act 2015
8.5.4.2 French Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.5.5 Italy
8.5.5.1 Italy: Government Cost Cutting Measures Impacting Market Growth
8.5.5.2 Italian Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.5.6 Spain
8.5.6.1 Spanish Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.6 China
8.6.1 Air Pollution Associated With Increasing Prevalence
8.6.2 Expansion Of Healthcare Coverage And Reimbursement In China
8.6.3 Chinese Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.7 Japan
8.7.1 Cedar Reforestation And The Hay Fever Epidemic
8.7.2 Genetically Modified Rice As Immunotherapy
8.7.3 Effects Of The Rising Levels Of Generic Drug Penetration
8.7.4 Japanese Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.8 Russia
8.8.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.8.2 Russian Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.9 India
8.9.1 The Impact Of The Drug Prices Control Order On Indian Pharma
8.9.2 India’s Expansion Of Healthcare Provision
8.9.3 Indian Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.10 Brazil
8.10.1 How Will Brazil’s Growing Healthcare Influence Allergic Rhinitis Drugs
8.10.2 Brazilian Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.11 Mexico
8.11.1 Are Multinationals Waking Up To Mexico’s Market Potential?
8.11.2 Mexican Allergic Rhinitis Drugs Market: Market Forecast 2015-2025
8.12 Rest of the World
8.12.1 Rest of the World Allergic Rhinitis Drugs Market: Market Forecast 2015-2025

9. Leading Companies In The Allergic Rhinitis Drugs Market, 2015-2025
9.1 Allergic Rhinitis Drugs – An Evolving Market Space
9.1.1 Leading Companies In The Allergic Rhinitis Drugs Market, 2015
9.1.2 Allergic Rhinitis Drugs Market: Leading Companies Forecast 2015-2025
9.1.3 Allergic Rhinitis Drugs: Changing Market Shares By Leading Companies 2015-2025
9.2 ALK-Abelló
9.2.1 ALK-Abelló: Allergic Rhinitis Drugs Portfolio, 2015
9.2.2 ALK-Abelló: Recent Developments
9.2.2.1 Progress In The Approval Process For House Dust Mite (HDM) SLIT-Tablet
9.2.2.2 ALK Collaborates With EddingPharm To Boost China Sales
9.2.2.3 Jext Product Recall And The Subsequent Recovery
9.2.3 ALK-Abelló: Sales Forecast 2015-2025
9.2.4 ALK-Abelló: Allergic Rhinitis Drug Development Pipeline, 2015
9.3 GlaxoSmithKline (GSK)
9.3.1 GlaxoSmithKline: Allergic Rhinitis Drugs Portfolio, 2015
9.3.2 GlaxoSmithKline: Recent Developments
9.3.2.1 GSK Asset Swap with Novartis To Restructure Consumer Health
9.3.2.2 GSK Divestment of OTC Products
9.3.3 GlaxoSmithKline: Sales Forecast 2015-2025
9.3.4 GlaxoSmithKline: Allergic Rhinitis Drug Development Pipeline, 2015
9.4 Johnson & Johnson
9.4.1 Johnson & Johnson: Allergic Rhinitis Drugs Portfolio, 2015
9.4.2 Johnson & Johnson: Recent Developments
9.4.2.1 Launch of Zyrtec Dissolve Tabs
9.4.2.2 Manufacturing Recalls At McNeil Consumer Healthcare
9.4.3 Johnson & Johnson: Sales Forecast 2015-2025
9.5 Kyowa Hakko Kirin
9.5.1 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Portfolio, 2015
9.5.2 Kyowa Hakko Kirin: Sales Forecast 2015-2025
9.6 Merck & Co.
9.6.1 Merck: Allergic Rhinitis Drugs Portfolio, 2015
9.6.2 Merck: Recent Developments
9.6.2.1 Bayer Acquires Merck’s Consumer Health Business
9.6.2.2 FDA Rejects Singulair OTC Switch
9.6.3 Merck: Sales Forecast 2015-2025
9.6.4 Merck: Allergic Rhinitis Drug Development Pipeline, 2015
9.7 Sanofi
9.7.1 Sanofi: Allergic Rhinitis Drugs Portfolio, 2015
9.7.2 Sanofi: Sales Forecast 2015-2025
9.8 Stallergenes
9.8.1 Stallergenes: Allergic Rhinitis Drugs portfolio, 2015
9.8.2 Stallergenes: Recent Developments
9.8.2.1 Stallergenes Acquires Argentinean Company Alergo Pharma
9.8.2.2 Greer Launches Oralair In The US
9.8.2.3 Proposed Merger With Greer
9.8.3 Stallergenes: Sales Forecast 2015-2025
9.8.4 Stallergenes: Allergic Rhinitis Drug Development Pipeline, 2015
9.9 UCB
9.9.1 UCB: Allergic Rhinitis Drugs Portfolio, 2015
9.9.2 UCB: Sales Forecast 2015-2025
9.10 Other Leading Companies Within The Allergic Rhinitis Drugs Market

10. Allergic Rhinitis Drugs: Research And Development Pipeline, 2015-2025
10.1 Trends And Developments In The Allergic Rhinitis Pipeline
10.2 The R&D Pipeline For Oral Antihistamine, 2015
10.2.1 Talion (bepotastine) – Mitsubishi Tanabe
10.2.2 ZPL-3893787 (histamine H4R antagonist) – Ziarco Pharma
10.2.3 ZPL-868087 (oral histamine H3R antagonist) – Ziarco Pharma
10.3 The R&D Pipeline For Intranasal Corticosteroids, 2015
10.3.1 APC-3000 (HFA inhaled corticosteroid) – Adamis Pharmaceuticals
10.3.2 S0597 (topical glucocorticoid) – Sun Pharmaceuticals
10.3.3 TBS-6 – Trimel Pharmaceuticals
10.4 The R&D Pipeline For Immunotherapy In Allergic Rhinitis, 2015
10.4.1 Actair (house dust mite SLIT; STG320) – Stallergenes/Shionogi & Co
10.4.2 AllerT (subcutaneous birch pollen immunotherapy) – Anergis
10.4.3 Cat-SPIRE and other -SPIRE Therapies (synthetic peptide immunoregulatory epitopes) – Circassia Pharmaceuticals
10.4.4 Depigoid Birch 5000 (birch pollen allergen extract, Leti Pharma
10.4.5 House Dust Mite SLIT-Tablet (MK-8237) – ALK-Abelló/Merck/Torii
10.4.6 Pollinex Quattro (subcutaneous immunotherapies) – Allergy Therapeutics
10.4.7 gp-ASIT+ (grass pollen allergen fragments) – Biotech Tools
10.4.8 Betula verrucosa (Bet v) 1 allergen – Stallergenes
10.5 The R&D Pipeline for Other Allergic Rhinitis Drugs
10.5.1 eN-Lac (Lactobacillus paracasei GMNL-32) – GenMont Biotech
10.5.2 S-555739 (prostaglandin D2 receptor antagonist) – Shionogi
10.5.3 DSP-3025/AZD-8848 (toll-like receptor 7 agonist) – Dainippon Sumitomo/ AstraZeneca
10.5.4 GSK2245035 (toll-like receptor 7 agonist) – GSK
10.5.5 HP-3060 (transdermal long-acting tape) – Hisamitsu
10.5.6 MRX-4 (anti-inflammatory agent) – Celsus Therapeutics
10.5.7 OC459 (OC000459) – Oxagen/ Atopix Therapeutics /Eleventa
10.5.8 ONO-4053 (prostaglandin D2 receptor antagonist) – Ono Pharmaceutical
10.5.9 WF10 (tetrachlorodecaoxygen chlorite matrix) – Nuvo Research
10.5.10 RPL554 (PDE-3/PDE-4 antagonist) – Verona Pharma
10.5.11 VTX-1463 (toll-like receptor 8 agonist) – VentiRx

11. Qualitative Analysis Of The Allergic Rhinitis Drugs Market, 2015-2025
11.1 Market Factors Influencing Allergic Rhinitis Drugs
11.2 SWOT Analysis Of The Global Allergic Rhinitis Drugs Market, 2015-2025
11.2.1 Strengths
11.2.1.1 OTC-Switch Facilitating Ease Of Consumer Access
11.2.1.2 The Established Role Of Allergic Rhinitis Drugs In Treatment
11.2.1.3 Allergic Rhinitis And The Rising Unmet Clinical Need
11.2.1.4 Rising Profile of Allergic Rhinitis In Various Regions Driving Healthcare Provision
11.2.2 Weaknesses
11.2.2.1 Intranasal Corticosteroids And Patients’ Satisfaction Rates
11.2.2.2 Increasing Penetration Of Generic Drug Products
11.2.2.3 The Challenge Raised By The Low Volume Of Pipeline Developments
11.2.3 Opportunities
11.2.3.1 Growth In Emerging Markets Outstripping Established Markets
11.2.3.2 Rx-to-OTC Switching And The Effects On Revenue Potential
11.2.3.3 Combination Drug Products Providing Rising Efficacy Profiles
11.2.3.4 The Emergence Of Immunotherapy In Allergic Rhinitis
11.2.4 Threats
11.2.4.1 Cost-Containment As A Growth Restraint
11.2.4.2 Rising Cost Of APIs And Manufacturing
11.2.4.3 Patent Expiries And The Resultant Loss Of Revenue
11.3 Porter’s Five Force Analysis Of The Global Allergic Rhinitis Drugs Market, 2015-2025
11.3.1 Power of Buyers
11.3.2 Power Of Suppliers
11.3.3 Threat of Substitutes
11.3.4 Threat Of New Entrants
11.3.5 Rivalry Among Competitors

12. Expert Opinions From Our Primary Research
12.1 Interview with Tonya Winders, President and Chief Executive Officer, Allergy & Asthma Network
12.1.1 Allergy and Asthma Network And The Organisation’s Work In Allergic Rhinitis
12.1.2 Education Efforts Being Implement By Allergy & Asthma Network
12.1.3 Changing Conditions And The Impact On Allergic Rhinitis Prevalence And Severity
12.1.4 Climatic Changes And Its Impact On Allergic Rhinitis Incidence
12.1.5 Immunotherapy – Regulatory Hurdles And Its Adoption
12.1.6 Future Trends – Immunotherapies, Regulatory Approvals, Reimbursement
12.1.7 Allergy & Asthma Network’s Plans For The Future
12.2 Interview with Amena Warner, Nurse Advisor at Allergy UK And President, International Nurses Group In Immunodeficiencies
12.2.1 Allergy UK And The Organisation’s Work In Allergic Rhinitis
12.2.2 Allergy UK’s Patient Education Efforts
12.2.3 The Challenges Associated With The Treatment Options Available To Allergic Rhinitis Patients
12.2.4 Familial And Environmental Factors Influencing Allergic Rhinitis Prevalence
12.2.5 Immunotherapy And Its Impact On The Treatment Landscape For Allergic Rhinitis
12.2.6 Sublingual Immunotherapies And The Expanding Repertoire Of Allergic Rhinitis Treatments
12.2.7 Allergy UK’s Future Plans In Patient Education And Treatment Access
12.3 Interview with Dr Apelles Econs MRCS LRCP, Consultant – Allergy & Nutrition, Allergy Medical UK
12.3.1 On The Aetiology And Progression Of Allergy And Allergic Conditions
12.3.2 Factors Driving Allergic Rhinitis And The Familial Link
12.3.3 Developments And New Technologies In Diagnosing Allergies
12.3.4 Future Trends In Allergic Rhinitis Treatment And Allergy Medical UK’s Plans For The Future

13. Conclusions
13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
13.2 Leading Sectors In The Allergic Rhinitis Drugs Market In 2014
13.3 Leading Regions In The Allergic Rhinitis Drugs Market In 2014
13.4 Leading Companies In The Allergic Rhinitis Drugs Market, 2014
13.5 What Does The Future Hold For Allergic Rhinitis Drugs?

List of Tables
Table 1.1 Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Country, 2014-2025 (Redacted Data)
Table 2.1 Leading Antihistamines for Allergic Rhinitis, 2015
Table 2.2 Leading Corticosteroids for Allergic Rhinitis, 2015
Table 2.3 Clinical Trial Phases
Table 3.1 The Global Allergic Rhinitis Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2014
Table 3.2 Top 10 Allergic Rhinitis Drugs: Revenue ($m) and Market Share (%) ,2014
Table 3.3 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 3.4 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Sector, 2014-2019, 2019-2025, 2014-2025
Table 3.5 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2014, 2019, 2025
Table 4.1 Top Drugs In The Intranasal Antihistamines Market: Revenue ($m) and Market Shares (%), 2014
Table 4.2 Intranasal Antihistamines Market: Market Forecast by Value ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 4.3 Intranasal Antihistamines Market: Market Forecast by Volume (Million Sprays, AGR%, CAGR%) by Leading Drug Types, 2014-2025
Table 4.4 The Global Intranasal Antihistamines Market: Market Share (%) by Value by Leading Drugs, 2014, 2019, 2025
Table 4.5 Patanase: Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.6 Astepro: Meda Pharma Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.7 Astelin: Meda Pharma Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.8 Dymista: Meda Pharma Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 4.9 Generic Intranasal Azelastine: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 4.10 Generic Intranasal Azelastine: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 4.11 Generic Intranasal Olopatadine: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 4.12 Generic Intranasal Olopatadine: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.1 Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m) and Market Shares (%), 2014
Table 5.2 Intranasal Corticosteroids Market: Market Forecast by Value ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 5.3 Intranasal Corticosteroids Market: Market Forecast by Volume (Million Sprays, AGR%, CAGR%) by Leading Drug Types, 2014-2025
Table 5.4 The Global Intranasal Corticosteroids Market: Market Share by Value (%) by Leading Drugs, 2014, 2019, 2025
Table 5.5 Nasonex: Merck Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.6 Nasonex: Merck Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.7 Avamys/Veramyst: GlaxoSmithKline Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.8 Avamys/Veramyst: GlaxoSmithKline Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.9 Flixonase/Flonase/Flonase-OTC: GlaxoSmithKline Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.10 Flixonase/Flonase/Flonase-OTC: GlaxoSmithKline Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.11 Rhinocort: AstraZeneca Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.12 Rhinocort: AstraZeneca Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.13 Omnaris: Dainippon Sumitomo/Takeda Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.14 Omnaris: Dainippon Sumitomo/Takeda Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.15 Nasacort/Nasacort-OTC: Sanofi Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.16 Nasacort/Nasacort-OTC: Sanofi Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.17 Beconase/Beconase AQ: GSK/Omega Pharma Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.18 Beconase/Beconase AQ: GSK/Omega Pharma Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.19 Qnasl: Teva Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.20 Qnasl: Teva Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.21 Zetonna: Dainippon Sumitomo Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.22 Zetonna: Dainippon Sumitomo Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.23 Generic Intranasal Beclometasone: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.24 Generic Intranasal Beclometasone: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.25 Generic Intranasal Budesonide: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.26 Generic Intranasal Budesonide: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.27 Generic Intranasal Flunisolide: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.28 Generic Intranasal Flunisolide: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.29 Generic Intranasal Fluticasone: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.30 Generic Intranasal Fluticasone: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.31 Generic Intranasal Mometasone: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.32 Generic Intranasal Mometasone: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 5.33 Generic Intranasal Triamcinolone: Sales Forecast by Value ($m, AGR%, CAGR%), 2014-2025
Table 5.34 Generic Intranasal Triamcinolone: Sales Forecast by Volume (Million Sprays, AGR%, CAGR%), 2014-2025
Table 6.1 Leading Oral Antihistamines: Revenues ($m) and Market Shares (%), 2014
Table 6.2 Oral Antihistamines Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
Table 6.3 The Global Oral Antihistamines Market: Market Share by Value (%) by Leading Drugs, 2014, 2019, 2025
Table 6.4 Allegra/Allegra-D/Allegra OTC: Sanofi Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.5 Zyrtec/Zyrtec-D: J&J/ UCB/ GSK Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.6 Claritin/Claritin OTC: Merck & Co/ Bayer Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.7 Xyzal: Sanofi/ UCB/ GSK Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.8 Allelock: Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.9 Clarinex: Merck Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.10 Ebastel: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.11 Talion: Mitsubishi Tanabe Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 6.12 Other Oral Antihistamines: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.1 Leading Allergic Rhinitis Immunotherapy Products: Revenues ($m) and Market Shares (%), 2014
Table 7.2 Allergic Rhinitis Immunotherapy: Market Forecast ($m, AGR%, CAGR%) by Leading Products, 2014-2025
Table 7.3 The Global Allergic Rhinitis Immunotherapy Market: Market Share by Value (%) by Leading Products, 2014, 2019, 2025
Table 7.4 Allergic Rhinitis Immunotherapy Market: Revenue ($m) and Market Share (%) by Immunotherapy Type, 2014
Table 7.5 Staloral: Stallergenes Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.6 Alutard SQ: ALK-Abelló Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.7 Grazax/Grastek: ALK-Abelló/Merck Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.8 Oralair: Stallergenes Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.9 Ragwitek: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 7.10 Other Allergic Rhinitis Immunotherapy Products: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.1 The Global Allergic Rhinitis Drugs Market: Market Size ($m) and Market Share (%) by Region, 2014
Table 8.2 Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2014-2025
Table 8.3 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Region, 2014-2019, 2019-2025, and 2014-2025
Table 8.4 The Global Allergic Rhinitis Drugs Market Forecast: Market Share (%) by Region, 2014, 2019, and 2025
Table 8.5 The US Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.6 US Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.7 The EU5 Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2025
Table 8.8 The EU5 Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and Market Share (%) by Country 2014
Table 8.9 The EU5 Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.10 The EU5 Allergic Rhinitis Drugs Market: Market Share (%) by Country, 2014, 2019, 2025
Table 8.11 The German Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.12 German Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.13 The UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.14 UK Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.15 The French Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.16 French Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.17 The Italian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.18 Italian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.19 The Spanish Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.20 Spanish Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.21 The Chinese Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.22 Chinese Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.23 The Japanese Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.24 Japanese Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.25 The Russian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.26 Russian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.27 The Indian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.28 Indian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.29 The Brazilian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.30 Brazilian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.31 The Mexican Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
Table 8.32 Mexican Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 8.33 The Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2025
Table 8.34 Rest of the World Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.1 Leading Companies In The Allergic Rhinitis Drug Market: Revenues ($m) and Market Shares (%), 2014
Table 9.2 Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Companies, 2014-2025
Table 9.3 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Leading Companies, 2014, 2019, 2025
Table 9.4 ALK- Abelló: Company Overview, 2015
Table 9.5 ALK-Abelló: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.6 GlaxoSmithKline: Company Overview, 2015
Table 9.7 GlaxoSmithKline: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.8 Johnson & Johnson: Company Overview, 2015
Table 9.9 Johnson & Johnson: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.10 Kyowa Hakko Kirin: Company Overview, 2015
Table 9.11 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.12 Merck & Co: Company Overview, 2015
Table 9.13 Merck & Co: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.14 Sanofi: Company Overview, 2015
Table 9.15 Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.16 Stallergenes: Company Overview, 2015
Table 9.17 Stallergenes: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 9.18 UCB: Company Overview, 2015
Table 9.19 UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
Table 10.1 Allergic Rhinitis: Oral Antihistamine Pipeline, 2015
Table 10.2 Allergic Rhinitis: Intranasal Corticosteroids Pipeline, 2015
Table 10.3 Allergic Rhinitis: Immunotherapy Pipeline, 2015
Table 10.4 Allergic Rhinitis: Other Pipeline Drugs, 2015
Table 11.1 SWOT Analysis of the Global Allergic Rhinitis Drugs Market, 2015-2025
Table 13.1 Global Allergic Rhinitis Drugs: Market Forecast ($m, CAGR%), 2014, 2018, 2021, 2025
Table 13.2 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m) by Region, 2014, 2018, 2021, 2025

List of Figures
Figure 1.1 Global Allergic Rhinitis Drugs Market: Market Sectors, 2015
Figure 1.2 Italian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%) 2014-2025 (Illustrative Data)
Figure 2.1 Role of Mast Cells and IgE in Allergic Rhinitis, 2015
Figure 3.1 The Global Allergic Rhinitis Drugs Market: Revenue ($m) by Sector, 2014
Figure 3.2 Top 10 Allergic Rhinitis Drugs: Market Shares (%), 2014
Figure 3.3 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%) by Sector, 2014-2025
Figure 3.4 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Sector, 2014-2019
Figure 3.5 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Sector, 2019-2025
Figure 3.6 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Sector, 2014-2025
Figure 3.7 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2014
Figure 3.8 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2019
Figure 3.9 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2025
Figure 4.1 Top Drugs In The Intranasal Antihistamines Market: Revenue ($m), 2014
Figure 4.2 Intranasal Antihistamines Market: Market Forecast by Value ($m, AGR%), 2014-2025
Figure 4.3 Intranasal Antihistamines Market: Revenue Forecast by Value ($m) by Leading Drugs, 2014-2025
Figure 4.4 Intranasal Antihistamines Market: Market Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 4.5 Intranasal Antihistamines Market: Sales Forecast (Million Sprays) by Leading Drug Types, 2014-2025
Figure 4.6 The Global Intranasal Antihistamines Market by Volume: Market Share (%) by Leading Drugs, 2014
Figure 4.7 The Global Intranasal Antihistamines Market by Volume: Market Share (%) by Leading Drugs, 2019
Figure 4.8 The Global Intranasal Antihistamines Market by Volume: Market Share (%) by Leading Drugs, 2025
Figure 4.9 Patanase: Novartis Sales Forecast ($m, AGR%), 2014-2025
Figure 4.10 Astepro: Meda Pharma Sales Forecast ($m, AGR%), 2014-2025
Figure 4.11 Astelin: Meda Pharma Sales Forecast ($m, AGR%), 2014-2025
Figure 4.12 Dymista: Meda Pharma Sales Forecast ($m, AGR%), 2014-2025
Figure 4.13 Generic Intranasal Azelastine: Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 4.14 Generic Intranasal Azelastine: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 4.15 Generic Intranasal Olopatadine: Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 4.16 Generic Intranasal Olopatadine: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.1 Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m), 2014
Figure 5.2 Intranasal Corticosteroids Market: Market Forecast by Value ($m, AGR%), 2014-2025
Figure 5.3 Intranasal Corticosteroids Market: Market Forecast by Value ($m) by Leading Drugs, 2014-2025
Figure 5.4 Intranasal Corticosteroids Market: Market Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.5 Intranasal Corticosteroids Market: Revenue Forecast by Volume (Million Sprays) by Leading Drug Types, 2014-2025
Figure 5.6 The Global Intranasal Corticosteroids Market: Market Share by Value (%) by Leading Drugs, 2014
Figure 5.7 The Global Intranasal Corticosteroids Market: Market Share by Value (%) by Leading Drugs, 2019
Figure 5.8 The Global Intranasal Corticosteroids Market: Market Share by Value (%) by Leading Drugs, 2025
Figure 5.9 Nasonex: Merck Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.10 Nasonex: Merck Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.11 Avamys/Veramyst: GlaxoSmithKline Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.12 Avamys/Veramyst: GlaxoSmithKline Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.13 Flixonase/Flonase/Flonase-OTC: GlaxoSmithKline Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.14 Flixonase/Flonase/Flonase-OTC: GlaxoSmithKline Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.15 Rhinocort: AstraZeneca Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.16 Rhinocort: AstraZeneca Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.17 Omnaris: Dainippon Sumitomo/Takeda Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.18 Omnaris: Dainippon Sumitomo/Takeda Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.19 Nasacort/Nasacort-OTC: Sanofi Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.20 Nasacort/Nasacort-OTC: Sanofi Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.21 Beconase/Beconase AQ: GSK/Omega Pharma Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.22 Beconase/Beconase AQ: GSK/Omega Pharma Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.23 Qnasl: Teva Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.24 Qnasl: Teva Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.25 Zetonna: Dainippon Sumitomo Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.26 Zetonna: Dainippon Sumitomo Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.27 Generic Intranasal Beclometasone: Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.28 Generic Intranasal Beclometasone: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.29 Generic Intranasal Budesonide: Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.30 Generic Intranasal Budesonide: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.31 Generic Intranasal Flunisolide: Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.32 Generic Intranasal Flunisolide: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.33 Generic Intranasal Fluticasone: Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.34 Generic Intranasal Fluticasone: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.35 Generic Intranasal Mometasone: Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.36 Generic Intranasal Mometasone: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 5.37 Generic Intranasal Triamcinolone: Sales Forecast by Value ($m, AGR%), 2014-2025
Figure 5.38 Generic Intranasal Triamcinolone: Sales Forecast by Volume (Million Sprays, AGR%), 2014-2025
Figure 6.1 Leading Oral Antihistamines: Revenue ($m), 2014
Figure 6.2 Oral Antihistamines Market: Market Forecast ($m, AGR%), 2014-2025
Figure 6.3 Oral Antihistamines Market: Market Forecast ($m) by Leading Drugs, 2014-2025
Figure 6.4 The Global Oral Antihistamines Market: Market Share by Value (%) by Leading Drugs, 2014
Figure 6.5 The Global Oral Antihistamines Market: Market Share by Value (%) by Leading Drugs, 2019
Figure 6.6 The Global Oral Antihistamines Market: Market Share by Value (%) by Leading Drugs, 2025
Figure 6.7 Allegra (Allegra Rx and Allegra OTC) Historical Sales ($m, AGR%),1995-2014
Figure 6.8 Allegra/Allegra-D/Allegra OTC: Sanofi Sales Forecast ($m, AGR%), 2014-2025
Figure 6.9 Zyrtec/Zyrtec-D: J&J/ UCB/ GSK Sales Forecast ($m, AGR%), 2014-2025
Figure 6.10 Claritin/Claritin OTC: Merck & Co/ Bayer Sales Forecast ($m, AGR%), 2014-2025
Figure 6.11 Xyzal: Sanofi/ UCB/ GSK Sales Forecast ($m, AGR%), 2014-2025
Figure 6.12 Allelock: Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2014-2025
Figure 6.13 Clarinex: Merck Sales Forecast ($m, AGR%), 2014-2025
Figure 6.14 Ebastel: Sales Forecast ($m, AGR%), 2014-2025
Figure 6.15 Talion: Mitsubishi Tanabe Sales Forecast ($m, AGR%), 2014-2025
Figure 6.16 Other Oral Antihistamines: Sales Forecast ($m, AGR%), 2014-2025
Figure 7.1 Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m), 2014
Figure 7.2 Allergic Rhinitis Immunotherapy: Market Forecast ($m, AGR%), 2014-2025
Figure 7.3 Allergic Rhinitis Immunotherapy: Market Forecast ($m) by Leading Products, 2014-2025
Figure 7.4 The Global Allergic Rhinitis Immunotherapy Market: Market Share by Value (%) by Leading Products, 2014
Figure 7.5 The Global Allergic Rhinitis Immunotherapy Market: Market Share by Value (%) by Leading Products, 2019
Figure 7.6 The Global Allergic Rhinitis Immunotherapy Market: Market Share by Value (%) by Leading Products, 2025
Figure 7.7 Allergic Rhinitis Immunotherapy Market: Market Share (%) by Immunotherapy Type, 2014
Figure 7.8 Staloral: Stallergenes Sales Forecast ($m, AGR%), 2014-2025
Figure 7.9 Alutard SQ: ALK-Abelló Sales Forecast ($m, AGR%), 2014-2025
Figure 7.10 Grazax/Grastek: ALK-Abelló/Merck Sales Forecast ($m, AGR%), 2014-2025
Figure 7.11 Oralair: Stallergenes Sales Forecast ($m, AGR%), 2014-2025
Figure 7.12 Ragwitek: Sales Forecast ($m, AGR%), 2014-2025
Figure 7.13 Other Allergic Rhinitis Immunotherapy Products: Sales Forecast ($m, AGR%), 2014-2025
Figure 8.1 The Global Allergic Rhinitis Drugs Market: Market Size ($m) by Region, 2014
Figure 8.2 US, EU5, China and Japan Allergic Rhinitis Drugs Market: Market Forecast ($m), 2014-2025
Figure 8.3 Brazil, Russia, India, and Mexico Allergic Rhinitis Drugs Market: Market Forecast ($m), 2014-2025
Figure 8.4 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Region, 2014-2019
Figure 8.5 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Region, 2019-2025
Figure 8.6 The Global Allergic Rhinitis Drugs Market Forecast: CAGR (%) by Region, 2014-2025
Figure 8.7 The Global Allergic Rhinitis Drugs Market Forecast: Market Share (%) by Region, 2014
Figure 8.8 The Global Allergic Rhinitis Drugs Market Forecast: Market Share (%) by Region, 2019
Figure 8.9 The Global Allergic Rhinitis Drugs Market Forecast: Market Share (%) by Region, 2025
Figure 8.10 US Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.11 The EU5 Allergic Rhinitis Drugs Market: Revenue ($m) by Country, 2014
Figure 8.12 Germany, France, UK, Italy, and Spain Allergic Rhinitis Drugs Market: Market Forecast ($m), 2014-2025
Figure 8.13 The EU5 Allergic Rhinitis Drugs Market: Market Share (%) by Country, 2014
Figure 8.14 The EU5 Allergic Rhinitis Drugs Market: Market Share (%) by Country, 2019
Figure 8.15 The EU5 Allergic Rhinitis Drugs Market: Market Share (%) by Country, 2025
Figure 8.16 German Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.17 UK Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.18 French Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.19 Italian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.20 Spanish Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.21 Chinese Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.22 Japanese Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.23 Russian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.24 Indian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.25 Brazilian Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.26 Mexican Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.27 Rest of the World Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 9.1 Leading Companies In The Allergic Rhinitis Drug Market: Revenues ($m), 2014
Figure 9.2 Allergic Rhinitis Drugs Market: Market Forecast ($m) by Leading Companies, 2014-2025
Figure 9.3 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Leading Companies, 2014
Figure 9.4 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Leading Companies, 2019
Figure 9.5 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Leading Companies, 2025
Figure 9.6 ALK-Abelló: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.7 GlaxoSmithKline: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.8 Johnson & Johnson: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.9 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.10 Merck & Co: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.11 Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.12 Stallergenes: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 9.13 UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2014-2025
Figure 11.1 Porter’s Five Force Analysis of the Allergic Rhinitis Drugs Market, 2015
Figure 13.1 Global Allergic Rhinitis Drugs: Market Forecast ($m), 2014, 2018, 2021, 2025
Figure 13.2 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m) by Region, 2014-2025

【レポートのキーワード】

アレルギー性鼻炎、アレルギー性鼻炎治療薬、抗ヒスタミン剤、コルチコステロイド、免疫療法、ワクチン、医療、製薬、医薬品

★調査レポート[アレルギー性鼻炎治療薬の世界市場予測:抗ヒスタミン剤、コルチコステロイド、免疫療法、ワクチン] ( Allergic Rhinitis Drugs Market Forecast 2015-2025 : Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines / VGAIN5091105) 販売に関する免責事項
[アレルギー性鼻炎治療薬の世界市場予測:抗ヒスタミン剤、コルチコステロイド、免疫療法、ワクチン] ( Allergic Rhinitis Drugs Market Forecast 2015-2025 : Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines / VGAIN5091105) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆